Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
- April -
May
-
June
-
July
-
August
-
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
- 2023 -
2024
April 2023 - 32 products
L
IP
Cabazitaxel Labatec 60
mg/6 ml
2447.84
2748.85
10 %
Concentrate for infusion: Cabazitaxelum 60mg / 6ml
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
CI
Sitagliptin-Metformin-
Mepha retard 50/500 mg
60
15.35
34.05
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Sitagliptin-Metformin-
Mepha retard 50/500 mg
160
40.31
62.75
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
●
B / SL / SG
FB
G
L
IP
Sitagliptin-Metformin-
Mepha retard 50/1000 mg
60
15.35
34.05
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Sitagliptin-Metformin-
Mepha retard 50/1000 mg
160
40.31
62.75
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Sitagliptin-Metformin-
Mepha retard 100/1000 mg
30
15.35
34.05
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Sitagliptin-Metformin-
Mepha retard 100/1000 mg
90
45.35
68.55
10 %
Tabletten mit veränderter Wirkstofffreisetzung: 2 Active Agents
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Daflon 1000
30
14.96
27.65
10 %
Chewing tablets: 2 Active Agents
Servier (Suisse) SA
D / SL
FB
G
L
IP
CI
Camzyos 2.5 mg
28
1403.91
1602.80
10 %
Capsules: Mavacamtenum 2.5 mg
Bristol-Myers Squibb SA
B / SL
FB
G
L
IP
Camzyos 5 mg
28
1403.91
1602.80
10 %
Capsules: Mavacamtenum 5 mg
Bristol-Myers Squibb SA
B / SL
FB
G
L
IP
Camzyos 10 mg
28
1403.91
1602.80
10 %
Capsules: Mavacamtenum 10 mg
Bristol-Myers Squibb SA
B / SL
FB
G
L
IP
Camzyos 15 mg
28
1403.91
1602.80
10 %
Capsules: Mavacamtenum 15 mg
Bristol-Myers Squibb SA
B / SL
FB
G
L
IP
CI
Lupkynis 7,9 mg
180
693.20
813.00
10 %
Weichkapsel: Voclosporinum 7.9 mg
Otsuka Pharmaceutical
(Switzerland) GmbH
B / SL
FB
G
IP
V/S
Comirnaty
Original/Omicron BA. 4-5
0.225 mg
10
PR
PR
k.A.
Pfizer AG
B
FB
G
IP
V/S
Comirnaty
Original/Omicron BA. 4-5
0.225 mg
10
PR
PR
k.A.
Pfizer AG
B
FB
G
IP
V/S
Comirnaty
Original/Omicron BA. 4-5
0.225 mg
195
PR
PR
k.A.
Pfizer AG
B
FB
G
IP
V/S
Glassia 20 mg/ml
PR
PR
k.A.
Infusion solution: Alpha-1-Proteinasi Inhibitor Humanum 1000mg / 50ml
Ideogen AG
B
FB
G
IP
Cabazitaxel Labatec 45
mg/4.5 ml
PR
PR
k.A.
Concentrate for infusion: Cabazitaxelum 45mg / 4.5ml
Labatec Pharma SA
A
FB
G
IP
Cabazitaxel Labatec 50
mg/5 ml
PR
PR
k.A.
Concentrate for infusion: Cabazitaxelum 50mg / 5ml
Labatec Pharma SA
A
FB
G
IP
Verdye 25 mg
5
PR
PR
k.A.
Dry substance: Viride Indocyaninum 25 mg
Mediconsult AG
A
FB
G
IP
CI
Aceduo Leman
30 g
PR
PR
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
IP
CI
Aceduo Leman
45 g
PR
PR
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
IP
CI
Aceduo Leman
60 g
PR
PR
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
milgamma 300 mg
10
PR
PR
k.A.
Coated tablets: Benfotiaminum 300 mg
Maras AG
D
FB
G
milgamma 300 mg
30
PR
PR
k.A.
Coated tablets: Benfotiaminum 300 mg
Maras AG
D
FB
G
milgamma 300 mg
60
PR
PR
k.A.
Coated tablets: Benfotiaminum 300 mg
Maras AG
D
FB
G
milgamma 300 mg
90
PR
PR
k.A.
Coated tablets: Benfotiaminum 300 mg
Maras AG
D
FB
G
milgamma 300 mg
100
PR
PR
k.A.
Coated tablets: Benfotiaminum 300 mg
Maras AG
D
FB
G
CM
Rivaroxaban vascular
Bayer 2.5mg
56
PR
PR
k.A.
Coated tablets: Rivaroxabanum 2.5 mg
Bayer (Schweiz) AG
B
FB
G
CM
Rivaroxaban vascular
Bayer 2.5mg
196
PR
PR
k.A.
Coated tablets: Rivaroxabanum 2.5 mg
Bayer (Schweiz) AG
B
FB
G
IP
CI
Fynzur 2,275 mg/ml
18 ml
PR
PR
k.A.
solution pour pulvérisation cutanée: Finasteridum 114 µg
Bailleul (Suisse) SA
B
FB
G
IP
CI
Fynzur 2,275 mg/ml
3 x 18 ml
PR
PR
k.A.
solution pour pulvérisation cutanée: Finasteridum 114 µg
Bailleul (Suisse) SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2024
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
